Chemours stock snapshot after recent gains

Chemours (CC) has caught investor attention after a recent run in its share price, with the stock up over the past week, month, past 3 months and year to date.

Chemours’ recent momentum has been strong, with a 30 day share price return of 40.17% and a year to date share price return of 49.55%, even though the 3 year total shareholder return sits at a 40.15% decline.

If this kind of sharp rebound has your attention, it could be a good moment to broaden your watchlist and check out 22 top founder-led companies as another way to spot interesting opportunities.

With Chemours trading at $18.32, sitting above the average analyst price target of $16.33 yet showing a 65% intrinsic discount estimate and a value score of 5, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 12.2% Overvalued

At $18.32, Chemours sits above the most followed fair value estimate of $16.33, which is built on detailed cash flow and earnings assumptions.

Secular demand growth for advanced materials tied to electrification, renewables, data centers, and energy storage is generating incremental sales in higher value applications for APM; ongoing portfolio optimization and pricing improvements in these segments are structurally enhancing net margins and improving earnings quality.

Want to see what is behind that earnings quality claim? The narrative leans on specific revenue growth, margin rebuild, and a future earnings multiple that might surprise you.

Result: Fair Value of $16.33 (OVERVALUED)

However, that story could change quickly if PFAS litigation leads to large cash payouts, or if tougher environmental rules squeeze Chemours’ margins more than expected.

Another View: Multiples Paint a Cheaper Picture

The narrative fair value of $16.33 suggests Chemours looks 12.2% overvalued at $18.32, but the market is sending a different signal. On a P/S of 0.5x, Chemours sits well below the US Chemicals industry at 1.1x, peers at 1.3x, and even its own fair ratio of 0.9x. That gap points to a valuation mismatch, but it is unclear whether this reflects a margin of safety for investors or a sign that the market is pricing in potential future challenges.

Build Your Own Chemours Narrative

If you are not fully convinced by this view or prefer to lean on your own work, you can build a complete Chemours story yourself in just a few minutes, starting with Do it your way.

A great starting point for your Chemours research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Chemours is on your radar, do not stop there. Put a few more ideas on your screen so you are not relying on a single story.

• Target potential value by scanning 53 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their financial profile.
• Focus on resilience by checking solid balance sheet and fundamentals stocks screener (45 results) that prioritise financial strength and balance sheet quality.
• Spot under followed opportunities by reviewing our screener containing 25 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.